

Vaccines Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit & Conjugate Vaccines, and Others), Technology [Recombinant Vaccines, mRNA Vaccines, Cell-Based Vaccines, Virus-Like Particles (VLPs), and Others], Application (Human Papillomavirus, Cancer, MMR, DPT, and Others), Route of Administration (Oral, Injectable, and Nasal), Age (Pediatric Vaccine and Adult Vaccine), End User (Healthcare Facilities, Vaccination Programs and Centers, and Others),(and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

<https://marketpublishers.com/r/V15F34BE2136EN.html>

Date: November 2023

Pages: 150

Price: US\$ 5,190.00 (Single User License)

ID: V15F34BE2136EN

Abstracts

The vaccines market is expected to grow from US\$ 135.28 billion in 2022 to US\$ 216.30 billion by 2030; it is expected to grow at a CAGR of 6.0% from 2022 to 2030. Rising prevalence of infectious diseases and an increase for uptake of vaccines amid the COVID-19 pandemic are a few factors driving the vaccines market growth.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. A vaccine typically preparation contains an agent responsible for resembling a disease-causing microorganism and is often made

from a weakened or killed form of the microbe, toxin, or one of its surface proteins. Vaccines can be prophylactic or therapeutic, offering immunity.

Market Opportunity

Therapeutic Vaccine Development

Traditional vaccines stimulate the production of antibodies and immune proteins that target specific pathogens like viruses and bacteria. Likewise, therapeutic vaccines stimulate the immune system to target cancer cells and control the progression of chronic infections like HIV. Further, therapeutic vaccines typically stimulate the recipient's immune system to slow or stop chronic disease progression or target cancer cells. Further, therapeutic vaccines for the treatment of noninfectious diseases encompass a wide variety of possible formulations, antigens, and mechanism of action. Therefore, therapeutic vaccines development will provide lucrative market opportunity for the forecast period 2022-2030.

Examples of Therapeutic Vaccines in Development

Indication Development Phase

Ovarian Cancer Phase 1

Multiple Myeloma Phase 1

Type 1 Diabetes Preclinical

Acute Myelogenous Leukemia 3

Mesothelioma 2

Source: TheInsight Partners Analysis

Market Insights

Rising Infectious Diseases

According to the Connecticut Department of Public Health report 2020, below are the infectious diseases recorded in 2020 in Connecticut.

Reported Cases of Connecticut Reportable Diseases in 2020

Disease Total

Hepatitis A 15

Influenza 98

Malaria 4

Tuberculosis 54

SARS-CoV-2 2,00,379

Source: TheInsight Partners Analysis

Additionally, the below table reveals notable infectious disease by the Center for Health Protection report in 2020:

Notable Infectious Disease

Disease Total

SARS-CoV-2 8847

Chickenpox 1987

Community-associated methicillin-resistant Staphylococcus aureus infection 813

Dengue Fever 22

Tuberculosis 3656

Source: TheInsight Partners Analysis

Among all the infectious diseases, SARS-CoV-2 was all time high during 2020 to 2022 period where other uptake of vaccines including Dengue, Chickenpox, Tuberculosis, and others were low. However, SARS-CoV-2 vaccines uptake was all time high due to

rising cases globally. According to the Public Health England report published in 2021, 12-month UK coverage for DTaP/IPV/Hib/HepB3 vaccination increased by 0.1% to 92.2% and Rotavirus by 0.3% to 90.6%. However, MenB2 decreased by 0.1, accounting for 92.3% compared to the previous year. Also, the NHS England report reveals that, in December 2022, a total of 88.9 of all adult care home residents had been vaccinated with a COVID-19 booster dose. Therefore, rising prevalence of infectious diseases, demand for vaccination is high resulting in overall market growth for the forecast period 2022-2030.

Type-Based Insights

Based on type, the vaccines market is segmented as live attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit & conjugate vaccines, and others. The live attenuated vaccines segment held the largest market share in 2022. Live attenuated vaccines are very effective vaccines used in the prevention of a variety of diseases, including influenza, chickenpox, measles, polio, and tuberculosis. As per the World Health Organization (WHO) report, there are around a billion cases of seasonal influenza, including 5 million cases of severe illness. Also, it causes around 290,000 to 650,000 respiratory deaths annually. Therefore, live-attenuated influenza vaccine (LAIV) proves advantageous to combat the infection among the population. For example, LAIV can provide upto 90% protection among adults under 65 years of age and upto 40% of adults over 65. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Based on application, the vaccines market is segregated into Human Papillomavirus (HPV), cancer, MMR, DPT, and others. The HPV segment held the largest market share in 2022. According to the WHO report, HPV is highly prevalent among women in Sub-Saharan Africa (24%), followed by Latin America and the Caribbean (16%), Eastern Europe (14%), and South-East Asia (14%). Also, 625,600 women and 694,000 men have HPV-related cancer annually globally. Also, in 2020, cervical cancer accounted for 93% of HPV-related cancers among women. Therefore, there is a high demand for HPV vaccines among the population due to rising prevalent cases, as these vaccines protect against genital warts and most cases of cervical cancer. Also, HPV vaccines are highly approved by the US Food and Drug Administration (USFDA). 'GARDASIL 9' is one such example of an HPV vaccine approved by the US FDA. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Route of Administration-Based Insights

In terms of route of administration, the vaccines market is categorized as oral, nasal, and injectable. The injectable segment held a larger share of the market in 2022. The most common route of vaccine administration is through the injectable route, as administering a vaccine through a subcutaneous or intradermal route may cause local irritation, skin discoloration, inflammation, and many more.

Further, the CDC report reveals that DTaP, DT, HepA, HepB, Hib, HPV, IIV4, RIV4, cclIV4, IPV*†, MenACWY, MenB, MMR‡ , PCV13, PPSV23*†, RZV, Td, Tdap, TT, VAR† are common vaccines administered through the injectable route of administration. Varied vaccines administered through injectable routes act as a standalone factor responsible for influential segment growth for the forecast period 2022-2030.

Contents

1. INTRODUCTION

- 1.1 Scope of the Study
- 1.2 Market Definition, Assumptions and Limitations
- 1.3 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights
- 2.2 Market Attractiveness Analysis

3. RESEARCH METHODOLOGY

4. VACCINES MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis
- 4.3 Ecosystem Analysis
 - 4.3.1 List of Vendors in the Value Chain

5. VACCINES MARKET - KEY MARKET DYNAMICS

- 5.1 Key Market Drivers
- 5.2 Key Market Restraints
- 5.3 Key Market Opportunities
- 5.4 Future Trends
- 5.5 Impact Analysis of Drivers and Restraints

6. VACCINES MARKET - GLOBAL MARKET ANALYSIS

- 6.1 Vaccines - Global Market Overview
- 6.2 Vaccines - Global Market and Forecast to 2030

7. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY TYPE, 2020-2030

- 7.1 Overview
- 7.2 Live Attenuated Vaccines
- 7.3 Inactivated Vaccines
- 7.4 Toxoid Vaccines
- 7.5 Subunit and Conjugate Vaccines
- 7.6 Others

8. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY TECHNOLOGY, 2020-2030

- 8.1 Overview
- 8.2 Recombinant Vaccines
- 8.3 mRNA Vaccines
- 8.4 Cell-Based Vaccines
- 8.5 Virus-Like Particles (VLPs)
- 8.6 Others

9. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY APPLICATION, 2020-2030

- 9.1 Overview
- 9.2 Human Papillomavirus (HPV)
- 9.3 Cancer
- 9.4 Measles, Mumps, Rubella (MMR)
- 9.5 Diphtheria, Pertusis, Tetanus (DPT)
- 9.6 Others

10. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY ROUTE OF ADMINISTRATION, 2020-2030

- 10.1 Overview
- 10.2 Oral
- 10.3 Injectable
- 10.4 Nasal

11. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY AGE, 2020-2030

- 11.1 Overview

11.2 Pediatric

11.3 Adult

12. VACCINES MARKET – REVENUE ANALYSIS (USD MILLION) – BY END USER, 2020-2030

12.1 Overview

12.2 Healthcare Facilities (HCF)

12.3 Vaccination Centers and Programs

12.4 Others

13. VACCINES MARKET - REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS

13.1 North America

13.1.1 North America Vaccines Market Overview

13.1.2 North America Vaccines Market Revenue and Forecasts to 2030

13.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Type

13.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology

13.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Application

13.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration

13.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Age

13.1.8 North America Vaccines Market Revenue and Forecasts and Analysis - By End User

13.1.9 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries

13.1.9.1 United States Vaccines Market

13.1.9.1.1 United States Vaccines Market, by Type

13.1.9.1.2 United States Vaccines Market, by Technology

13.1.9.1.3 United States Vaccines Market, by Application

13.1.9.1.4 United States Vaccines Market, by Route of Administration

13.1.9.1.5 United States Vaccines Market, by Age

13.1.9.1.6 United States Vaccines Market, by End User

13.1.9.2 Canada Vaccines Market

13.1.9.2.1 Canada Vaccines Market, by Type

- 13.1.9.2.2 Canada Vaccines Market, by Technology
- 13.1.9.2.3 Canada Vaccines Market, by Application
- 13.1.9.2.4 Canada Vaccines Market, by Route of Administration
- 13.1.9.2.5 Canada Vaccines Market, by Age
- 13.1.9.2.6 Canada Vaccines Market, by End User

13.1.9.3 Mexico Vaccines Market

- 13.1.9.3.1 Mexico Vaccines Market, by Type
- 13.1.9.3.2 Mexico Vaccines Market, by Technology
- 13.1.9.3.3 Mexico Vaccines Market, by Application
- 13.1.9.3.4 Mexico Vaccines Market, by Route of Administration
- 13.1.9.3.5 Mexico Vaccines Market, by Age
- 13.1.9.3.6 Mexico Vaccines Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

13.2 Europe

- 13.2.1 Germany
- 13.2.2 France
- 13.2.3 Italy
- 13.2.4 Spain
- 13.2.5 United Kingdom
- 13.2.6 Rest of Europe

13.3 Asia-Pacific

- 13.3.1 Australia
- 13.3.2 China
- 13.3.3 India
- 13.3.4 Japan
- 13.3.5 South Korea
- 13.3.6 Rest of Asia-Pacific

13.4 Middle East and Africa

- 13.4.1 South Africa
- 13.4.2 Saudi Arabia
- 13.4.3 U.A.E
- 13.4.4 Rest of Middle East and Africa

13.5 South and Central America

- 13.5.1 Brazil
- 13.5.2 Argentina
- 13.5.3 Rest of South and Central America

14. PRE AND POST COVID-19 IMPACT

15. INDUSTRY LANDSCAPE

- 15.1 Mergers and Acquisitions
- 15.2 Agreements, Collaborations, Joint Ventures
- 15.3 New Product Launches
- 15.4 Expansions and Other Strategic Developments

16. COMPETITIVE LANDSCAPE

- 16.1 Heat Map Analysis by Key Players
- 16.2 Company Positioning and Concentration

17. VACCINES MARKET - KEY COMPANY PROFILES

- 17.1 GSK
 - 17.1.1 Key Facts
 - 17.1.2 Business Description
 - 17.1.3 Products and Services
 - 17.1.4 Financial Overview
 - 17.1.5 SWOT Analysis
 - 17.1.6 Key Developments

Note - Similar information would be provided for below list of companies

- 17.2 Pfizer
- 17.3 Sanofi
- 17.4 Merck
- 17.5 Serum Institute of India (SII)
- 17.6 AstraZeneca
- 17.7 BioNTech
- 17.8 Biological E
- 17.9 Sinovac
- 17.10 Sinopharm
- 17.11 Bharat Biotech

18. APPENDIX

- 18.1 Glossary
- 18.2 About The Insight Partners
- 18.3 Market Intelligence Cloud

I would like to order

Product name: Vaccines Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit & Conjugate Vaccines, and Others), Technology [Recombinant Vaccines, mRNA Vaccines, Cell-Based Vaccines, Virus-Like Particles (VLPs), and Others], Application (Human Papillomavirus, Cancer, MMR, DPT, and Others), Route of Administration (Oral, Injectable, and Nasal), Age (Pediatric Vaccine and Adult Vaccine), End User (Healthcare Facilities, Vaccination Programs and Centers, and Others),(and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

Product link: <https://marketpublishers.com/r/V15F34BE2136EN.html>

Price: US\$ 5,190.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V15F34BE2136EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970